150 related articles for article (PubMed ID: 17194352)
1. [The use of the Framingham-REGICOR equation in a primary care centre. Impact on primary prevention of cardiovascular diseases].
Parrilla Valero F; Segura Benedicto A; Segú Tolsa JL
Aten Primaria; 2006 Nov; 38(9):490-5. PubMed ID: 17194352
[TBL] [Abstract][Full Text] [Related]
2. Controversies in dyslipidaemia management.
Stock J
Atherosclerosis; 2012 Apr; 221(2):321-4. PubMed ID: 22305261
[No Abstract] [Full Text] [Related]
3. The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona.
Herrera S; Guelar A; Sorlì L; Vila J; Molas E; Grau M; Marrugat J; Esteve E; Güerri-Fernández R; Montero M; Knobel H
HIV Clin Trials; 2016 Jul; 17(4):131-9. PubMed ID: 27169692
[TBL] [Abstract][Full Text] [Related]
4. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the SCORE and REGICOR models for calculating cardiovascular risk in cardiovascular disease-free individuals at a healthcare center in Barcelona, Spain].
Baena Díez JM; del Val Garcia JL; Héctor Salas Gaetgens L; Sánchez Pérez R; Altes Vaques E; Deixens Martínez B; Amatller Corominas M; Katia Núñez Casillas D
Rev Esp Salud Publica; 2005; 79(4):453-64. PubMed ID: 16465962
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of coronary risk estimates derived using the Framingham and REGICOR equations].
Cristóbal J; Lago F; de la Fuente J; González-Juanatey JR; Vázquez-Bellés P; Vila M
Rev Esp Cardiol; 2005 Aug; 58(8):910-5. PubMed ID: 16053824
[TBL] [Abstract][Full Text] [Related]
7. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside.
Kazi DS; Virani SS
Prog Cardiovasc Dis; 2019; 62(5):406-413. PubMed ID: 31672610
[TBL] [Abstract][Full Text] [Related]
8. Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study.
Buitrago F; Calvo-Hueros JI; Cañón-Barroso L; Pozuelos-Estrada G; Molina-Martínez L; Espigares-Arroyo M; Galán-González JA; Lillo-Bravo FJ
Ann Fam Med; 2011; 9(5):431-8. PubMed ID: 21911762
[TBL] [Abstract][Full Text] [Related]
9. [Predictive capacity, comparison and clinic consequences of the Framingham-Wilson and REGICOR tables in persons for whom care has been provided at a health care center, Badajoz, Spain].
Cañón Barroso L; Díaz Herrera N; Cruces Muro E; Nieto Hernández T; Garrote Florencio T; Buitrago F
Rev Esp Salud Publica; 2007; 81(4):353-64. PubMed ID: 18041538
[TBL] [Abstract][Full Text] [Related]
10. Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study.
Barroso LC; Muro EC; Herrera ND; Ochoa GF; Hueros JI; Buitrago F
Scand J Prim Health Care; 2010 Dec; 28(4):242-8. PubMed ID: 20873973
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment].
Buitrago F; Cañón-Barroso L; Díaz-Herrera N; Cruces-Muro E; Escobar-Fernández M; Serrano-Arias JM
Rev Esp Cardiol; 2007 Feb; 60(2):139-47. PubMed ID: 17338879
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
13. [Carotid intima-media thickness distribution according to the stratification of cardiovascular risk by means of Framingham-REGICOR and score function charts].
Hermida-Ameijeiras Á; López-Paz JE; Riveiro-Cruz MA; Calvo-Gómez C
Hipertens Riesgo Vasc; 2016; 33(2):51-7. PubMed ID: 26796100
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
15. Impact of coronary artery calcium on cardiovascular risk categorization and lipid-lowering drug eligibility in asymptomatic hypercholesterolemic men.
Chironi G; Simon A; Megnien JL; Sirieix ME; Mousseaux E; Pessana F; Armentano R
Int J Cardiol; 2011 Sep; 151(2):200-4. PubMed ID: 20580446
[TBL] [Abstract][Full Text] [Related]
16. Association Between Improvement in Cardiovascular Risk Profile and Changes in Sickness Absence: Results of the ICARIA Study.
Calvo-Bonacho E; Catalina-Romero C; Cabrera M; Fernández-Labandera C; Sánchez Chaparro MÁ; Brotons C; Ruilope LM
Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):941-951. PubMed ID: 28291729
[TBL] [Abstract][Full Text] [Related]
17. [Calculation of coronary risk in primary care: which table is more suitable for our patients?].
Rodríguez Villar D; Muñoz Devesa L; García López UP
Aten Primaria; 2007 Mar; 39(3):145-9. PubMed ID: 17386207
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cardiovascular risk in primary care patients in France.
Bruckert E; Bonnelye G; Thomas-Delecourt F; André L; Delaage PH
Arch Cardiovasc Dis; 2011; 104(6-7):381-7. PubMed ID: 21798470
[TBL] [Abstract][Full Text] [Related]
20. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey.
Salami JA; Warraich HJ; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Katzen BT; Lloyd-Jones D; Krumholz HM; Nasir K
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
